Regenxbio Inc., of Rockville, Md. completed a heavily oversubscribed $70.5 million series D financing, bringing the total capital raised by the company since inception to more than $110 million. Regenxbio said it plans to use the proceeds to advance its lead programs through clinical development, build out its clinical and manufacturing infrastructure, expand its team and add to its current pipeline of adeno-associated viral vector-based gene therapies.